The strategy, described in the Journal of Translational Medicine, is what the investigators call reaction-based chemical shift engineering. Rather than trying to untangle overlapping resonances with ever more sophisticated pulse sequences or higher magnetic fields, the team sidestepped the problem entirely. They designed a molecular probe that reacts selectively with a chosen target — in their proof-of-concept study, the neurotransmitter norepinephrine — and converts it into a new chemical species whose protons resonate far outside the crowded endogenous window. The product of the reaction, 4-hydroxybutanal, carries an aldehyde proton that rings out at approximately 9.7 parts per million, a spectral neighborhood essentially deserted by the metabolites of living tissue and safely distant from the towering water signal that dominates every in vivo proton spectrum.

The choice of norepinephrine was no accident. This catecholamine neurotransmitter sits at the center of the brain’s arousal and reward circuitry, and disturbances in its signaling have been implicated in depression for decades — indeed, some of the most widely prescribed antidepressants, including fluoxetine, are thought to modulate noradrenergic tone among their downstream effects. Yet norepinephrine has been notoriously difficult to observe in a living brain. Optical probes cannot penetrate the skull, positron emission tomography tracers offer limited chemical specificity, and conventional spectroscopy cannot pick the molecule out of the dense thicket of overlapping signals. A probe that renders norepinephrine visible as a clean, isolated peak would therefore fill a genuine gap in both neuroscience research and translational drug development.

The probe itself, designated FS, works through a cascade of nucleophilic substitution reactions. When it encounters norepinephrine, the catecholamine’s amine and hydroxyl groups attack the probe in sequence, triggering a chemical rearrangement that liberates 4-hydroxybutanal as the detectable product. The team did not simply assert this mechanism; they supported it with theoretical simulations that mapped the reaction pathway and predicted the chemical shift of the resulting aldehyde proton. That computational grounding matters, because the entire strategy hinges on a quantitative prediction: that the product’s resonance would land at a frequency far enough from every endogenous signal to be resolved cleanly even at the moderate field strengths available in clinical and preclinical settings.

Validation proceeded in careful steps, from the test tube to the living brain. In aqueous solutions, the probe showed favorable selectivity for norepinephrine over a panel of structurally related catecholamines and other biological amines, along with robust resistance to interference and stability across the physiological pH range — properties that are essential for any reagent intended to function in the chemically noisy environment of cells and blood. The investigators then moved to PC12 cells, a widely used model line derived from rat adrenal tissue that differentiates into neuron-like cells and secretes catecholamines. Inside these cells, the probe successfully detected endogenous norepinephrine release, demonstrating that it could function not merely against purified standards but against the genuine molecular inventory of a living cell.

The decisive test came in vivo. Working on a 7.0 Tesla magnetic resonance system — a field strength common in preclinical research and increasingly in human imaging — the team administered the probe to live rats that had been treated with fluoxetine, a pharmacological manipulation expected to elevate norepinephrine signaling in the brain. The characteristic aldehyde resonance near 9.7 parts per million appeared in the spectra of the treated animals, providing what the researchers describe as in vivo monitoring of pharmacologically elevated norepinephrine. In other words, for the first time in this experimental context, a specific neurotransmitter could be tracked in a living brain as a single, interference-free spectroscopic peak, using the same fundamental physics that powers every clinical MRI scanner.

The technical significance of this achievement is worth unpacking for readers who do not live and breathe spectroscopy. Chemical shift — the tiny displacement of a nucleus’s resonance frequency caused by its electronic environment — is the fundamental currency of magnetic resonance spectroscopy. Aldehyde protons are among the most deshielded protons in organic chemistry, which is why they resonate at such high parts-per-million values. By designing a reaction that manufactures an aldehyde in situ, the team effectively hijacked the extreme end of the chemical shift scale as a private detection channel. No pulse-sequence trickery, no spectral deconvolution, no isotope labeling with its attendant cost and regulatory burden: just a targeted chemical transformation that moves the signal out of the crowd. The approach is, in principle, generalizable — any analyte for which a selective reaction can be devised that yields a product with a distinctive chemical shift becomes a candidate for the same treatment.

The translational implications stretch across several domains. In disease diagnosis, an interference-free window would allow clinicians to quantify specific biomarkers in the brain or in tumors with a specificity that conventional proton spectroscopy cannot deliver, potentially distinguishing pathological biochemistry from normal variation. In dynamic metabolic monitoring, the ability to follow a neurotransmitter’s fluctuations over time could illuminate how psychiatric medications actually reshape brain chemistry in individual patients. In preclinical drug evaluation, the method offers pharmaceutical researchers a non-invasive readout of target engagement in animal models — a way to confirm that an experimental compound genuinely changes the neurochemical landscape it is designed to change, without sacrificing the animals at each time point. The authors frame the work as establishing a generalizable strategy for expanding the metabolic detection scope of proton MRS, and the framing seems justified by the breadth of those applications.

Caveats remain, as they always do on the road from proof of concept to bedside. The study was conducted in rats at 7 Tesla with a probe administered exogenously, and the safety, pharmacokinetics, and clearance of such probes in humans would require extensive evaluation before any clinical deployment. The sensitivity of the method — how little norepinephrine can be detected, and how quickly — will determine whether it can capture the fast, transient dynamics of neurotransmission or only slower, tonic changes. And for each new target molecule, chemists will need to design a new probe with the right selectivity, kinetics, and biocompatibility, a nontrivial task that the elegant norepinephrine example does not automatically solve for every analyte. Still, the conceptual barrier that has constrained proton spectroscopy for half a century — the crowding of all endogenous signals into a few parts per million — has now been shown to be circumventable by design rather than by brute force.

What makes this work resonate beyond its immediate field is the way it reframes a classic instrumentation problem as a chemistry problem. For decades, the response to spectral congestion in magnetic resonance has been to build bigger magnets and cleverer sequences. This team’s answer was to reach into the molecule itself and rearrange it. If reaction-based chemical shift engineering proves as adaptable as its creators suggest, the crowded 1-to-5-ppm window that has defined the limits of proton spectroscopy may no longer be the whole story — and the quiet, empty region beyond 5 parts per million could become a busy new address for the molecules of the mind.

Subject of Research: Reaction-based chemical shift engineering for interference-free in vivo proton magnetic resonance spectroscopy of norepinephrine

Article Title: Reaction-based chemical shift engineering unlocks interference-free detection window for in vivo proton magnetic resonance spectroscopy

Article References: Lv, G., Gao, J., Qi, M., Meng, X., Tang, H., Han, F., & Zhang, J. (2026). Reaction-based chemical shift engineering unlocks interference-free detection window for in vivo proton magnetic resonance spectroscopy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08931-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08931-3

Keywords: magnetic resonance spectroscopy, chemical shift, molecular probes, norepinephrine, depression, neurotransmitters, in vivo imaging, fluoxetine, preclinical imaging, molecular imaging, brain metabolism, translational medicine

The research team, based at Brigham and Women’s Hospital, followed thirty wild-type pups from three litters through four developmental milestones: postnatal day 0 (P0), day 8 (P8), day 21 (P21), and eight weeks of age. Using the VisualSonics Vevo F2 high-frequency ultrasound system with transducers operating between 25 and 71 MHz, the investigators captured images of hearts beating at rates of 400 to 600 beats per minute with exceptional spatial and temporal resolution. At birth, when a pup weighs barely more than a gram and its left ventricle measures roughly 1.5 millimeters across, imaging was performed without anesthesia or hair removal, with animals gently restrained on a heated platform. From P8 onward, a standardized isoflurane protocol maintained heart rates above 400 beats per minute while body temperature was held at 37 degrees Celsius, minimizing the hemodynamic variability that anesthesia can otherwise introduce.

The structural findings chart an astonishing trajectory of growth. Body weight rose from 1.25 grams at birth to nearly 21 grams at adulthood, while the left ventricular end-diastolic volume expanded almost tenfold, from about 6.4 microliters to 59 microliters. Ventricular walls thickened in parallel, with the systolic anterior wall more than doubling from birth to weaning and continuing to grow into adulthood. Perhaps most intriguing was the behavior of body-weight-indexed left ventricular mass, which surged during the early postnatal and juvenile periods before declining toward adult values. This transient overshoot, the authors note, mirrors the well-described postnatal transition in which cardiomyocytes shift from proliferative expansion to hypertrophic growth, with the heart briefly outpacing the body before mass and body weight rescale proportionally at maturity.

Counterintuitively, conventional indices of pumping performance declined steadily across development. Ejection fraction fell from 69 percent at birth to 60 percent at eight weeks, and fractional shortening followed a similar downward path. Rather than signaling weakening hearts, the authors explain, this decline reflects geometry and loading: as the ventricular cavity expands disproportionately relative to stroke volume, and as systemic afterload rises with maturation, volumetric efficiency measures naturally decrease even as the heart muscle itself grows stronger. Crucially, the strain measurements told a different story. Global circumferential strain, endocardial circumferential strain, and global radial strain all remained statistically stable from P8 through adulthood, indicating that the intrinsic contractile machinery of the myocardium is established early and preserved intact through the storms of growth and remodeling.

Strain analysis, enabled by speckle-tracking software that follows the natural acoustic markers within heart tissue frame by frame, quantifies how much the ventricular wall deforms during each beat. Longitudinal strain captures shortening along the base-to-apex axis, circumferential strain measures shortening around the chamber’s circumference, and radial strain records wall thickening toward the cavity. Because these indices depend on the coordinated behavior of individual contractile units rather than on chamber geometry, they are considered exquisitely sensitive detectors of early dysfunction, often flagging impairment in disease models long before ejection fraction budges. The one strain parameter that did change was myocardial global longitudinal strain, which became significantly more negative, from minus 8.8 percent at P8 to minus 11.9 percent at P21, suggesting selective maturation of the longitudinal contractile pathway during the juvenile period.

Diastolic function, the heart’s capacity to relax and fill, matured along its own timetable. From P8 onward, early and late transmitral filling velocities climbed steadily, with the E/A ratio peaking at day eight before stabilizing. Tissue Doppler velocities at the mitral annulus, including the early relaxation velocity e-prime, the late atrial contraction velocity a-prime, and the systolic annular velocity s-prime, all increased progressively into adulthood. Right ventricular function, tracked through tricuspid annular plane systolic excursion, nearly doubled from 0.40 millimeters at P8 to 0.78 millimeters at eight weeks. Left atrial areas grew in step with the rest of the heart, though fractional area change fluctuated without a consistent directional trend. These trajectories align with known postnatal refinements in calcium-handling proteins such as SERCA2a and ryanodine receptor 2, and with the metabolic switch from glycolysis to fatty-acid oxidation that newborn cardiomyocytes undergo shortly after birth.

One of the study’s most striking discoveries emerged when the data were split by sex. Most conventional parameters showed no sex-specific developmental patterns, but strain imaging revealed a clear divergence in late adolescence. By eight weeks, males exhibited significantly more negative longitudinal strain and higher radial strain than females, and systolic annular velocity showed the same pattern, with males reaching 21.5 millimeters per second versus 17.3 in females. Stroke volume also displayed a significant time-by-sex interaction. The timing is telling: the divergence between P21 and week eight coincides with pubertal maturation and the surge in circulating androgens, and it is consistent with prior work showing that isolated cardiomyocytes from adult male mice contract more vigorously than those from females, likely through testosterone-driven modulation of calcium handling and myofilament function.

Notably, this mouse pattern inverts the human picture, where women typically show greater myocardial strain values than men. The authors point to fundamental species differences as likely explanations: adult mouse ventricles predominantly express the fast-kinet ics alpha myosin heavy chain, whereas human ventricles express the slower beta isoform, and the tenfold difference in resting heart rate between the species fundamentally alters contraction-relaxation dynamics. Sex differences in cardiac function are also dynamic across the lifespan; aging studies suggest the male advantage seen at eight weeks may reverse later in life, with females maintaining better contractility into old age. For researchers translating murine findings to human cardiology, the message is unambiguous: sex- and species-specific normative values are essential, and extrapolating adult or human reference ranges to neonatal and juvenile mice risks misjudging both disease severity and therapeutic efficacy.

The study also functions as a technical manual for a notoriously difficult measurement. The authors document a systematic 12.3 percent overestimation of ejection fraction by short-axis M-mode derived from the Teichholz formula compared with B-mode Simpson’s monoplane volumetry, a bias that persisted at every developmental stage and that they recommend accounting for, particularly in disease models with regional wall motion abnormalities. They further emphasize maintaining normothermia in neonatal pups, which cannot thermoregulate and are prone to hypothermia-induced bradycardia, transferring maternal scent to gloved hands before handling to prevent rejection by dams, positioning the M-mode cursor perpendicular to the septum at the mid-papillary level while avoiding papillary muscle inclusion, and keeping Doppler angles below 45 degrees to prevent velocity underestimation. A printable echocardiography quicksheet summarizing key reference values accompanies the publication as a bench-side tool.

The limitations are candidly acknowledged: the data derive exclusively from Jackson Laboratory C57BL/6 mice, whose developmental trajectories may differ across strains; volumetric parameters rest on geometric assumptions that strain measurements avoid; and the extreme technical constraints of imaging newborn hearts meant that strain, Doppler, and right ventricular assessments could not be performed at P0. Future directions include comprehensive right ventricular and large-vessel characterization, integration with invasive pressure-volume loop analysis, and extending the serial observations into aging to trace how the early-life sex differences evolve across the lifespan. For now, the study stands as the definitive developmental atlas of the laboratory mouse heart, one that promises to sharpen the interpretation of countless cardiac disease models and, by reducing misclassification of phenotypes, to trim both animal usage and cost in preclinical research.

Subject of Research: Postnatal cardiac development and myocardial strain in C57BL/6 mice assessed by high-frequency echocardiography

Article Title: Prospective echocardiographic characterization of postnatal cardiac development in C57BL/6 mice: Strain analysis between birth and adulthood

Article References: Jo, S., Spyropoulos, G., Hart, L. G., Covington, T. A., Pandey, A. K., Michel, T., & Spyropoulos, F. (2026). Prospective echocardiographic characterization of postnatal cardiac development in C57BL/6 mice: Strain analysis between birth and adulthood. Physiological Reports, 14(18), Article e71113. https://doi.org/10.14814/phy2.71113

Image Credits: AI Generated

DOI: 10.14814/phy2.71113

Keywords: echocardiography, strain analysis, C57BL/6 mice, cardiac development, speckle-tracking, ejection fraction, diastolic function, sexual dimorphism, left ventricle, normative values, preclinical imaging, Physiological Reports

Glioblastoma remains one of medicine’s most formidable opponents. Median survival after diagnosis is still under a year despite surgery, radiation and chemotherapy, and magnetic resonance imaging, the clinical workhorse for tumor detection, frequently underestimates how far malignant cells have infiltrated surrounding brain tissue. Because cutting away more of the tumor margin measurably delays progression, clinicians have a strong incentive to see the tumor and its microenvironment more clearly. That is where PET comes in. Rather than showing anatomy, PET can reveal molecular activity, and one target has drawn particular attention: the 18-kDa translocator protein, or TSPO, which sits on the outer membranes of mitochondria in activated immune cells.

In glioblastoma, TSPO lights up on two cell types that define the tumor microenvironment: tumor-associated microglia and macrophages, the inflammatory cells the tumor recruits and manipulates, and, crucially, the glioma cells themselves, which previous work has shown are actually the dominant cellular source of TSPO signal in this disease. The radiotracer [18F]GE-180 was developed to bind TSPO with high affinity, and preclinical and clinical studies have demonstrated robust tracer accumulation in TSPO-expressing gliomas. Yet [18F]GE-180 penetrates the intact healthy brain poorly, and critics have argued that in tumors the signal might largely reflect passive flooding of tissue through a leaky blood-brain barrier rather than genuine binding to the target protein. The debate has split the imaging community and complicated the tracer’s interpretation in the clinic.

The Munich-based research team, led by Leonie Hoermann, Laura M. Bartos and Matthias Brendel of LMU University Hospital, designed an unusually rigorous set of experiments to settle the question. They worked with mice implanted with SB28, a weakly immunogenic mouse glioblastoma line that grows in an intact immune system, imaging the animals at an early stage one week after implantation and a late stage three weeks in. Each mouse received [18F]GE-180 and underwent a dynamic 60-minute microPET scan. Critically, some animals first received a massive dose of non-radioactive GE-180, 25,000 times in excess of the tracer dose. This cold ligand saturates every available TSPO binding site, so any radioactivity that still accumulates after blocking cannot be specific binding and must instead come from non-specific processes such as passive extravasation. Comparing blocked and unblocked scans therefore quantifies the true specific fraction of the signal.

The results were striking. In early-stage tumors, blocking wiped out 72 percent of the PET signal, indicating that nearly three quarters of what the scanner saw was genuine, displaceable binding. In late-stage tumors, the blockable fraction dropped to 59 percent. Contralateral hemispheres and sham-injected animals showed reductions in the 61 to 68 percent range, but the absolute drop in distribution volume was substantially larger inside tumors, confirming a bigger pool of specifically bound tracer there. To rule out tracer-specific quirks, the team repeated key experiments with [18F]DPA-714, an independent TSPO radioligand, and observed comparable blocking effects. Ex vivo gamma counting of dissected tissue corroborated the in vivo findings, showing a 55 percent radioactivity reduction in tumor after blocking versus 28 percent in non-tumor tissue.

The next question was whether the specific signal could be trusted at the level of individual cells. Here the team deployed a technique the group calls scRadiotracing: injecting the radioactive tracer into living animals, then dissociating the tumors and sorting the cells with immunomagnetic separation and flow cytometry before measuring radioactivity in each cell fraction with an ultra-sensitive gamma counter. When cells came from blocked animals, their radioactive burden collapsed. Tumor cells showed 95 percent less uptake after blocking, tumor-associated microglia and macrophages 98 percent less, and remaining cells 99 percent less, with the pattern holding at both tumor stages and in sham animals. In other words, virtually every radioactive molecule inside a cell was bound specifically to TSPO. The specificity problem, wherever it existed, was not a cellular one.

That left the extracellular compartment. To measure blood-brain barrier disruption directly, the researchers injected a fluorescent dextran with a molecular weight of 3,000 daltons into the bloodstream. The molecule is small enough to slip through a disrupted barrier but far too large to cross an intact one, making it a clean readout of pathological permeability. Confocal microscopy of brain sections revealed that dextran extravasation surged as tumors progressed, with the fluorescence intensity sum increasing roughly sevenfold from early to late stage. Most tellingly, the amount of dextran leakage correlated strongly with the residual PET signal that survived blocking (a correlation coefficient of 0.809) and inversely with the percentage reduction achieved by blocking (R = -0.824). Bigger, leakier tumors carried proportionally more non-specific signal.

The team also exploited the natural heterogeneity of glioblastoma to answer a subtle follow-up question: does barrier disruption merely add background noise, or does it also boost the specific signal by delivering more tracer to cells? Dividing tumors into twenty regional clusters and comparing blocked with unblocked scans in the same animals, they found no correlation between regional residual signal, a surrogate of local barrier leakiness, and the regionally specific signal. Cellular tracer uptake, in other words, was not being driven open-barrier delivery. Combined with the near-complete blocking of every cell fraction, this allowed the researchers to allocate the entire non-specific TSPO-PET signal to the extracellular compartment, where free tracer pools in tissue flooded through a broken barrier without ever entering a cell.

The findings reconcile what had seemed like contradictory positions in the literature. Skeptics who called [18F]GE-180 a failed radioligand were right that a substantial and variable slice of its signal tracks barrier disruption rather than the target protein. Advocates who pointed to robust tracer accumulation in gliomas were also right that the majority of the signal, particularly early in disease, represents true molecular binding inside tumor cells and immune cells. Both phenomena coexist, and their balance shifts as the tumor grows, its vasculature remodels and increasingly leaks. The practical implication for imaging specialists is that TSPO-PET remains a genuinely specific window on the glioblastoma microenvironment, but interpretation must account for tumor size and stage, because the non-specific extracellular component grows with disease progression.

The implications stretch well beyond one tracer. Blood-brain barrier disruption complicates the interpretation of molecular imaging and drug delivery across the entire spectrum of brain disease, and vascular permeability varies dramatically between tumor regions and across disease time courses. The methodological framework established here, pairing blocking studies with single-cell radiotracer allocation and direct permeability measurement in the same animal, can now be applied to other PET tracers used in glioma imaging and to other neurological conditions in which the barrier is compromised. The authors note limitations, including the use of a single tumor cell line and exclusively female mice, and previous studies have reported sex-related differences in TSPO expression and tracer uptake that future work will need to address. Still, for a field that has argued for years over what its scans really see, this study provides something rarer than a new tracer: a quantitative map of exactly where the light comes from.

Subject of Research: Specificity of TSPO-PET imaging signals and blood-brain barrier disruption in experimental glioblastoma

Article Title: Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma

Article References: Hoermann, L., Seker, F. B., Joseph, E., Kirchleitner, S. V., Blobner, J., Kunze, L. H., Thevis, J. F., Hummel, S., Englert, A. L., Wind-Mark, K., Holzgreve, A., Lindner, S., Werner, R. A., von Baumgarten, L., Albert, N. L., Plesnila, N., Brendel, M., & Bartos, L. M. (2026). Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08187-5

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08187-5

Keywords: glioblastoma, TSPO-PET, blood-brain barrier, radiotracer specificity, GE-180, tumor microenvironment, microglia, macrophages, molecular imaging, scRadiotracing, DPA-714, preclinical imaging

To appreciate why this matters, one must first understand the stubborn technical difficulties that have long constrained rodent fMRI. Mapping brain-wide networks in behaving animals remains a formidable challenge for reasons rooted in the basic mechanics of magnetic resonance. Conventional fMRI relies on echo-planar imaging sequences that generate loud acoustic noise, often exceeding one hundred decibels inside the scanner bore. For a human volunteer lying still with ear protection, that noise is an annoyance. For a mouse, an animal whose hearing is far more sensitive and whose experimental value depends on natural behavior, the acoustic barrage is a confound of the first order. It activates auditory circuits, triggers stress responses, alters arousal, and contaminates precisely those network signals researchers hope to measure.

The problem compounds when the goal is to image animals that are awake and moving. Standard echo-planar sequences are exquisitely sensitive to motion, and even the small head movements of a behaving mouse produce artifacts that can dwarf the subtle blood-oxygenation-level-dependent signals of interest. Traditional workarounds, such as anesthetizing animals or restraining their heads while training them to tolerate the scanner, solve one problem by creating another. Anesthesia suppresses consciousness and reorganizes neural dynamics, so the networks measured under it are not the networks of a behaving animal. Head fixation permits imaging during limited tasks but rules out the rich, ethologically meaningful behaviors, navigation, social interaction, foraging, that make rodents so valuable as models in the first place.

SORDINO-fMRI addresses both obstacles at once. The framework is silent, eliminating the acoustic confound that plagues conventional sequences, and it is motion-resistant by design, so that the global dynamics of freely orchestrating animals can be captured without the ghosting, blurring, and signal dropout that normally accompany movement in the magnet. According to the News & Views summary, the method captures global dynamics during complex behaviors in mice while enabling artifact-free simultaneous network-level recordings with cellular or chemical validation. That last clause deserves emphasis: SORDINO-fMRI does not operate in isolation but can be paired, in the same scanning session, with techniques that read out neural activity or neurochemistry at the cellular scale. This creates a rare multimodal platform in which whole-brain network dynamics and mechanistic ground truth can be acquired in parallel.

The significance of this convergence becomes clear when one considers how neuroscience has been pulled in two directions by its tools. On one side, techniques such as widefield calcium imaging, two-photon microscopy, and high-density electrophysiology offer cellular or near-cellular resolution, but each covers only a limited field of view. Landmark large-scale efforts, including work from the International Brain Laboratory and the population recordings of Stringer and colleagues as well as Steinmetz, Zatka-Haas, Carandini, and Harris, have shown how much can be learned from recording many neurons or many brain regions simultaneously. Yet even hundreds of targeted probes cannot deliver a truly brain-wide picture in a small rodent brain without gaps. On the other side, fMRI delivers that brain-wide coverage but has historically lacked cellular specificity and, in rodents, behavioral realism. SORDINO-fMRI aims to close this gap, bringing whole-brain functional imaging into the awake, behaving regime where modern systems neuroscience now lives.

The timing of this advance is not accidental. The past several years have seen an intensifying effort to legitimize and improve rodent fMRI as a translational bridge between human imaging and circuit neuroscience. Reviews and methodological papers by Gao and colleagues, by Mandino, Vujic, Grandjean, and Lake, and by Daley, Pan, Kaundinya, and Keilholz have catalogued both the promise and the pitfalls of preclinical fMRI, from anesthesia confounds to the challenge of interpreting blood-oxygenation signals in a brain the size of a hazelnut. Studies by Yu and colleagues, and by Bolt and colleagues, have pushed toward whole-brain imaging of neural dynamics, while Rauscher and colleagues and Pagani and colleagues have recently expanded the frontier of what functional imaging in rodents can reveal. Lake and colleagues established foundations for imaging neural activity in awake animals that have informed the field’s trajectory. Shemesh’s commentary situates SORDINO-fMRI squarely within this arc, arguing that it opens new opportunities in preclinical imaging and systems neuroscience.

What might those opportunities look like in practice? Consider a mouse navigating a virtual or physical maze while its brain is imaged silently. Because the animal is awake and behaving, the researchers can ask how distributed networks, hippocampal, cortical, subcortical, coordinate in real time as the animal makes decisions, encodes space, or responds to rewards. Because the readout is artifact-free, fluctuations in the blood-oxygenation signal can be attributed to neural dynamics rather than to head motion or acoustic startle. And because simultaneous cellular or chemical validation is possible, the researchers can anchor the macroscopic network measurements to known quantities: the firing of specific neuronal populations, or the release of specific neuromodulators. This triangulation across scales is precisely what the field has needed to translate insights about circuit mechanisms into models that can be tested against human brain imaging, and vice versa.

The preclinical implications extend into translational medicine. Rodent models are indispensable for studying neurological and psychiatric disease, from Parkinson’s and epilepsy to depression and schizophrenia, but the field has long struggled with the failure of therapies that succeed in mice and fail in humans. A significant part of that failure is measurement: preclinical readouts often do not correspond to the outcome measures used in clinical trials. A method that can image brain-wide network function in behaving disease-model mice, with the same modality, fMRI, that is used in patients, offers a more direct translational axis. Network-level phenotypes measured with SORDINO-fMRI could, in principle, be compared quantitatively with resting-state and task-based networks in human patients, enabling a more rigorous back-and-forth between bench and bedside.

None of this diminishes the substantial work that remains. Interpreting fMRI signals in rodents requires careful attention to neurovascular coupling, which may differ across species, brain regions, and behavioral states. Combining fMRI with optogenetics, electrophysiology, or pharmacology in the same session demands exquisite engineering, from radiofrequency-compatible hardware to protocols that keep animals healthy and cooperative inside a magnet. Shemesh, who directs research at the Weizmann Institute of Science and the Champalimaud Foundation and who has long championed advanced diffusion and functional MRI methods, is well placed to evaluate these challenges, and his commentary treats SORDINO-fMRI as a genuine advance rather than a finished solution. He discloses service on the scientific advisory board of Bruker Biospin, a reminder that the industrial ecosystem around preclinical imaging is actively engaged with these developments.

Still, the phrase that will linger with readers is the one Shemesh chose for his title: a silent leap. The word silent is literal, a reference to the acoustically quiet acquisition that makes natural behavior possible inside the scanner. But it also captures the way this methodological shift arrives without fanfare amid the louder headlines of AI models and brain-computer interfaces, quietly removing constraints that have shaped decades of experimental design. If SORDINO-fMRI performs as described, the neuroscience community gains something it has never had before: a way to watch entire mammalian brains orchestrate real behavior, at network scale, validated at the cellular level, all in a single experiment. For preclinical imaging and systems neuroscience alike, that is not an incremental improvement. It is a change in what questions can be asked at all, and the answers to those questions may reshape how we understand the brain in motion, in health, and in disease.

One useful way to situate the advance is through the physics of the blood-oxygenation-level-dependent signal itself. Because the hemodynamic response that fMRI measures unfolds over roughly a second or more, it is inherently slower than the millisecond-timescale spiking that electrophysiology captures, and its amplitude depends on local neurovascular mechanisms rather than on neural activity alone. This is why pairing network-level imaging with cellular or chemical readouts in the same session is so valuable: it allows investigators to calibrate what the vascular signal actually reflects under a given behavioral state, rather than assuming that coupling parameters measured in anesthetized preparations carry over unchanged.

The multimodal design also speaks to a broader trend in systems neuroscience toward convergent evidence. When a macroscopic network fluctuation can be checked against, for example, the concurrent firing of a defined neuronal population or the release of a neuromodulator, interpretations move from plausible to testable. Such cross-scale validation has historically required separate experiments in separate animals, introducing variability that complicates comparison. Acquiring the modalities simultaneously in the same animal ties them together temporally, so that a transient change in global dynamics can be linked to its cellular substrate at the very moment it occurs. For preclinical studies of disease models, where network alterations may be subtle and state-dependent, that temporal alignment could prove as consequential as the silence and motion resistance themselves.

Subject of Research: A silent, motion-resistant fMRI framework for brain-wide imaging of behaving mice

Article Title: A silent leap in neuroimaging

Article References: Shemesh, N. (2026). A silent leap in neuroimaging. Nature Neuroscience. https://doi.org/10.1038/s41593-026-02401-1

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02401-1

Keywords: SORDINO-fMRI, functional MRI, neuroimaging, rodent brain imaging, awake behaving mice, brain networks, systems neuroscience, preclinical imaging, Nature Neuroscience, Noam Shemesh, MacKinnon, silent fMRI